Registry for patients with chronic lymphocytic leukemia and related conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry focuses on the long-term follow-up of patients diagnosed with chronic lymphocytic leukemia (CLL) and related conditions such as B-prolymphocytic leukemia, T-cell prolymphocytic leukemia, and others. The study aims to assess overall survival and progression-free survival, while also evaluating late toxicities associated with various treatments. By collecting extensive clinical data, the registry seeks to analyze the outcomes of different therapies and their long-term effects on patients. This comprehensive approach will help in understanding the disease better and improving future treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria (all must apply)

1. Confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK-LGL, HCL or Richter's transformation
2. 18 years of age or older
3. Signed, written informed consent
4. Presence of one or more of the following disease situations:

   * Newly diagnosed patients without treatment indication (eligible for watch and wait Approach Treatment within a clinical trial according to the AMG or status post participation in a clinical Trial)
   * Treatment with standard therapies approved for the eligible entities or status post treatment (outside of clinical trials)
   * Referral for evaluation the indication for HSCT
   * Relapsed disease status (even if first diagnosis was prior to activation of the registry)

Exclusion Criteria

1. Patients without confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK- LGL, HCL or Richter's transformation
2. Cerebral dysfunction, legal incapacity

Where it's running

• BAG Freiberg-Richter, Jacobasch, Wolf, Illmer
  Dresden, Saxony, Germany Recruiting

Study contacts

• Study coordinator: Anna-Maria Fink, MD
• Email: cllstudie@uk-koeln.de
• Phone: +4922147888220

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rocbrutinib versus pirtobrutinib for adults with relapsed or refractory CLL/SLL after a covalent BTK inhibitor

  This compares rocbrutinib and pirtobrutinib to see which works better and is safer for adults whose CLL or SLL returned or didn't respond after a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Newave Pharmaceutical Inc · Skokie, Illinois and 6 other locations · NCT07342478

• Anti‑CD19 CAR‑T plus a BTK inhibitor for newly diagnosed high‑risk CLL/SLL

  We will try combining anti‑CD19 CAR‑T cells with a BTK inhibitor as first‑line treatment for people newly diagnosed with high‑risk CLL or SLL.

  Recruiting The Affiliated Hospital of Xuzhou Medical University · Xuzhou, Jiangsu · NCT07120633

• Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL

  This trial will try giving subcutaneous epcoritamab for up to 12 cycles to adults with CLL/SLL who have been on a second‑generation BTK inhibitor for at least 12 months to see if it can deepen responses to a complete remission with undetectable MRD so therapy can be stopped.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07108998

• National longitudinal cohort for large granular lymphocytic leukemia (LGLL)

  This project will collect past and ongoing medical data to test what factors affect diagnosis, treatments, and outcomes for people in China with T-LGL or NK-LGL leukemia.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07019766

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Thalidomide treatment for symptomatic large granular lymphocytic leukemia

  This study is testing if thalidomide can help people with symptomatic large granular lymphocytic leukemia feel better by seeing how well it works on its own.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06530576

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.